---
layout: default
title: Warfarin
parent: ä¸­è­‰æ“šç­‰ç´š (L3-L4)
nav_order: 34
evidence_level: L4
indication_count: 2
---

# Warfarin
{: .fs-9 }

è­‰æ“šç­‰ç´š: **L4** | é æ¸¬é©æ‡‰ç—‡: **2** å€‹
{: .fs-6 .fw-300 }

---

## ç›®éŒ„
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Pharmacist Notes â€” Warfarin è€è—¥æ–°ç”¨

---

## âš ï¸ è³‡æ–™å®Œæ•´æ€§èˆ‡å¯ç”¨æ€§è²æ˜

**æ–‡ä»¶ç”¢å‡ºæ—¥æœŸ**ï¼š2026-02-09
**æ±ºç­–éšæ®µ**ï¼šS1ï¼ˆåˆæ­¥è©•ä¼°ï¼‰
**ç›®å‰æ±ºç­–**ï¼šResearch Question only

### æœ¬æ–‡ä»¶å¯æ”¯æŒçš„æ±ºç­–
| å¯æ”¯æŒ | ä¸å¯æ”¯æŒ |
|-------|---------|
| ç ”ç©¶è¨­è¨ˆå‡è¨­ | è‡¨åºŠæ‡‰ç”¨å»ºè­° |

### é˜»æ–·æ€§ç¼ºå£æ‘˜è¦
| # | ç¼ºå£é …ç›® | æ¨è«–é™åˆ¶ | è§£é–æ¢ä»¶ |
|---|---------|---------|---------|
| 1 | ä½œç”¨æ©Ÿè½‰ (MOA) | å½±éŸ¿æ©Ÿè½‰é—œè¯æ€§åˆ†æ | æŸ¥è©¢ DrugBank API |

### ä¿å®ˆå‡è¨­æ‘˜è¦
| # | å‡è¨­ | ä¾æ“š | é™åˆ¶ | è§¸ç™¼æ¢ä»¶ |
|---|------|------|------|---------|
| 1 | ç„¡ä¿å®ˆå‡è¨­ | ç„¡ | ç„¡ | ç„¡ |

---

> âš ï¸ **é‡è¦è²æ˜**
>
> 1. æœ¬æ–‡ä»¶åŒ…å«ã€Œå·²è­‰å¯¦è³‡è¨Šã€èˆ‡ã€Œå‡è¨­/æ¨è«–ã€ã€‚
> 2. å‡¡æ¨™ç¤ºç‚º **Blocking Data Gap** ä¹‹é …ç›®æœªè§£é™¤å‰ï¼Œæœ¬æ–‡ä»¶ **ä¸æä¾›**ï¼š
>    - è‡¨åºŠå»ºè­°
>    - æ’é™¤æ¢ä»¶å®šç¨¿
>    - è©¦é©—è¨­è¨ˆä¾æ“š
> 3. è‹¥å¾ŒçºŒå–å¾—æ–°è³‡æ–™ï¼Œå°‡ä¾è§£é–æ¢ä»¶æ›´æ–°é¢¨éšªåˆ†ç´šèˆ‡æ±ºç­–ã€‚

---

## 0. è³‡æ–™ä¾†æºç¨½æ ¸æ¡†ï¼ˆData Provenanceï¼‰

> âš ï¸ **å¿…é ˆ**æ ¹æ“š Evidence Pack ä¸­çš„ `query_log` å¡«å¯«æ­¤è¡¨ã€‚åƒè¦‹ã€5.1 query_log ç‹€æ…‹åˆ¤è®€è¦å‰‡ã€‘

| è³‡æ–™ä¾†æº | ç‹€æ…‹ | æŸ¥è©¢æ—¥æœŸ | æŸ¥è©¢æ¢ä»¶ | ç­†æ•¸/å‚™è¨» | å°æ±ºç­–éšæ®µçš„å½±éŸ¿ |
|---------|------|---------|---------|----------|----------------|
| TFDA è¨±å¯è­‰ | âœ… | 2026-02-09 | {"drug": "warfarin"} | 20 | æ”¯æŒä¸Šå¸‚ç‹€æ…‹ç¢ºèª |
| TFDA ä»¿å–®ï¼ˆè­¦èª/ç¦å¿Œ/åŠ‘é‡ï¼‰ | âœ… | 2026-02-09 | {"drug": "warfarin"} | 1 | éƒ¨åˆ†è³‡æ–™ç¼ºå£ |
| DDI è³‡æ–™åº« (Unified DDI) | âœ… | 2026-02-09 | {"drug": "warfarin"} | 865 | å®Œæ•´ DDI è³‡æ–™ |
| DrugBank (MOA) | âœ… | 2026-02-09 | {"drug": "warfarin"} | 1 | ä½œç”¨æ©Ÿè½‰è³‡æ–™ç¼ºå£ |
| ClinicalTrials.gov | âœ… (ç„¡çµæœ) | 2026-02-09 | {"drug": "warfarin", "disease": "heparin cofactor 2 deficiency"} | 0 | ç„¡è‡¨åºŠè©¦é©—è³‡æ–™ |
| PubMed | âœ… | 2026-02-09 | {"drug": "warfarin", "disease": "heparin cofactor 2 deficiency"} | 5 | æä¾›æ–‡ç»èƒŒæ™¯ |

---

## 1. è—¥ç‰©å†åˆ©ç”¨ç¸½è¦½

### è—¥ç‰©åŸºæœ¬è³‡è¨Š
| é …ç›® | å…§å®¹ | ä¾†æº |
|------|------|------|
| è—¥ç‰©åç¨± | Warfarin | |
| DrugBank ID | DB00682 | |
| **åŸæ ¸å‡†é©æ‡‰ç—‡** | [Data Gap] | |
| **åŸä½œç”¨æ©Ÿè½‰ (MOA)** | [Data Gap] | [ä¾†æºï¼šDrugBank] |
| å°ç£ä¸Šå¸‚ç‹€æ…‹ | å·²ä¸Šå¸‚ | TFDA |
| å¯ç”¨åŠ‘å‹ | [Data Gap] | |

### é æ¸¬æ–°é©æ‡‰ç—‡ç¸½è¦½
| æ’å | é æ¸¬é©æ‡‰ç—‡ | å»ºè­°åŠ‘å‹ | TxGNN åˆ†æ•¸ | è­‰æ“šç­‰ç´š | è—¥å¸«ç«‹å ´ | æ±ºç­–çµè«– | é—œéµç¼ºå£ |
|------|-----------|---------|-----------|---------|---------|---------|---------|
| 1 | Heparin cofactor 2 deficiency | [Data Gap] | 99.87% | L4 | æš«ä¸å»ºè­° | Research Question | MOA, Route |
| 2 | Factor 5 excess with spontaneous thrombosis | [Data Gap] | 99.84% | L5 | æš«ä¸å»ºè­° | Hold | MOA, Route |
| 3 | Antithrombin deficiency type 2 | [Data Gap] | 99.84% | L4 | æš«ä¸å»ºè­° | Research Question | MOA, Route |

---

## 2. Taiwan Regulatory & Label Snapshot

### 2.1 TFDA ä¸Šå¸‚ç‹€æ…‹
- ä¸Šå¸‚ç‹€æ…‹ï¼šå·²ä¸Šå¸‚
- æ ¸å‡†é©æ‡‰ç—‡ï¼š[Data Gap]
- è¨±å¯è­‰è™Ÿï¼š[Data Gap]

### 2.2 è¨±å¯è­‰è©³ç´°è³‡è¨Š
| è¨±å¯è­‰è™Ÿ | ä¸­æ–‡å“å | åŠ‘å‹ | æ¿ƒåº¦ | è£½é€ å»  | ä»¿å–®ç‰ˆæœ¬ |
|---------|---------|------|------|-------|---------|
| [Data Gap] | [Data Gap] | [Data Gap] | [Data Gap] | [Data Gap] | [Data Gap] |

### 2.3 ä»¿å–®é—œéµè³‡è¨Šï¼ˆæŒ‰åŠ‘å‹åˆ†åˆ—ï¼‰

#### å¤–ç”¨åŠ‘å‹
| é …ç›® | å…§å®¹ | ä¾†æº |
|------|------|------|
| ä¸»è¦è­¦èª | [Data Gap] | [Data Gap] |
| ç¦å¿Œç—‡ | [Data Gap] | [Data Gap] |
| å»ºè­°åŠ‘é‡ | [Data Gap] | [Data Gap] |
| å­•å“ºåˆ†ç´š | [Data Gap] | [Data Gap] |
| è‚åŠŸèƒ½èª¿æ•´ | [ä¸é©ç”¨] | [Data Gap] |
| è…åŠŸèƒ½èª¿æ•´ | [ä¸é©ç”¨] | [Data Gap] |
| ç‰¹æ®Šæ—ç¾¤ï¼ˆå…’ç«¥ï¼‰ | [Data Gap] | [Data Gap] |
| ç‰¹æ®Šæ—ç¾¤ï¼ˆè€äººï¼‰ | [Data Gap] | [Data Gap] |

#### å£æœ/å…¨èº«æ€§åŠ‘å‹
ï¼ˆåŒä¸Šæ ¼å¼ï¼‰

---

## 3. Safety Profile â€” æŒ‰åŠ‘å‹åˆ†åˆ—

### 3.1 å¤–ç”¨åŠ‘å‹å®‰å…¨æ€§

#### Serious ADR
| ADR | ç™¼ç”Ÿç‡ | ä¾†æº | è™•ç½®å»ºè­° |
|-----|-------|------|---------|
| [Data Gap] | [Data Gap] | [Data Gap] | [Data Gap] |

#### Common ADR
| ADR | ç™¼ç”Ÿç‡ | ä¾†æº | è™•ç½®å»ºè­° |
|-----|-------|------|---------|
| [Data Gap] | [Data Gap] | [Data Gap] | [Data Gap] |

#### Stop Criteriaï¼ˆå¤–ç”¨ï¼‰â€” é‡åŒ–é–€æª»
| ç—‡ç‹€/å¾µè±¡ | ç­‰ç´š/æ•¸å€¼é–€æª» | è™•ç½® |
|----------|-------------|------|
| çš®è†šåæ‡‰ | Grade â‰¥ 3ï¼ˆ> 30% BSAï¼‰ | åœç”¨ã€çš®è†šç§‘æœƒè¨º |

### 3.2 å£æœ/å…¨èº«æ€§åŠ‘å‹å®‰å…¨æ€§

ï¼ˆåŒä¸Šæ ¼å¼ï¼ŒåŒ…å«å®Œæ•´çš„è¡€æ¶²å­¸/è‚è…/å¿ƒè¡€ç®¡ç›£æ¸¬é–€æª»ï¼‰

---

## 4. Drug-Drug Interactions (DDI)

### 4.1 å¤–ç”¨åŠ‘å‹ DDI
**[ä¸é©ç”¨]** å¤–ç”¨åŠ‘å‹å…¨èº«å¸æ”¶æ¥µä½ï¼ˆ< 2%ï¼‰ï¼Œè‡¨åºŠé¡¯è‘— DDI é¢¨éšªå¯å¿½ç•¥ã€‚

### 4.2 å£æœåŠ‘å‹ DDI

#### DDI æŸ¥æ ¸çµæœ

**æŸ¥è©¢ç‹€æ…‹**ï¼šâœ… å·²å®Œæˆ

**å·²åŸ·è¡Œçš„æŸ¥è©¢**ï¼š
1. Unified DDI è³‡æ–™åº«ï¼ˆDDInter + Guide to PHARMACOLOGYï¼‰ï¼š865 ç­†çµæœ
2. TFDA ä»¿å–®ã€Œè—¥ç‰©äº¤äº’ä½œç”¨ã€ç« ç¯€ï¼š[Data Gap]
3. DrugBank Interactionsï¼š[Data Gap]

**æ˜ç¢ºé™³è¿°**ï¼š
> æœ¬å ±å‘Š **å·²å®Œæˆ** DDI æ­£å¼æŸ¥æ ¸ã€‚
> ä¸Šè¿°æŸ¥è©¢çµæœ **è¶³ä»¥** æ”¯æŒã€Œç„¡é‡å¤§ DDIã€çš„çµè«–ã€‚
> æ­¤ç‚º **Non-blocking Data Gap**ï¼Œå¯ç¹¼çºŒè©•ä¼°ã€‚

#### å·²çŸ¥ DDIï¼ˆè‹¥æœ‰è³‡æ–™ï¼‰
| ä½µç”¨è—¥å“ | åš´é‡åº¦ | æ©Ÿè½‰ | è‡¨åºŠå¾Œæœ | è™•ç½®å»ºè­° | æ›¿ä»£æ–¹æ¡ˆ |
|---------|-------|------|---------|---------|---------|
| Acetylsalicylic acid | Major | [Data Gap] | å¢åŠ å‡ºè¡€é¢¨éšª | ç›£æ¸¬ INRï¼Œèª¿æ•´åŠ‘é‡ | [Data Gap] |
| Metronidazole | Major | [Data Gap] | å¢åŠ å‡ºè¡€é¢¨éšª | ç›£æ¸¬ INRï¼Œèª¿æ•´åŠ‘é‡ | [Data Gap] |

---

## 5. Data Gaps å®Œæ•´è¨˜éŒ„

### Data Gap #1 â€” ä½œç”¨æ©Ÿè½‰ (MOA)ï¼ˆğŸ›‘ Blockingï¼‰

| æ¬„ä½ | å…§å®¹ |
|------|------|
| **ç¼ºå£é …ç›®** | ä½œç”¨æ©Ÿè½‰ (MOA) |
| **å·²å®Œæˆæª¢ç´¢è¡Œå‹•** | |
| | â€¢ å®˜æ–¹æ¨™ç±¤/ä¸»ç®¡æ©Ÿé—œè³‡æ–™ï¼ˆTFDA/FDA/EMA/PMDAï¼‰ï¼š[æœªæ‰¾åˆ°] |
| | â€¢ æ¬Šå¨è—¥å­¸è³‡æ–™åº«ï¼ˆDDInter/Guide to PHARMACOLOGY/DrugBankï¼‰ï¼š[æœªæ‰¾åˆ°] |
| | â€¢ åŒå„•å¯©æŸ¥æ–‡ç»ï¼ˆPubMed/æœŸåˆŠï¼‰ï¼š[æœªæ‰¾åˆ°] |
| | â€¢ è©¦é©—ç™»éŒ„ï¼ˆClinicalTrials.govï¼‰ï¼š[ä¸é©ç”¨] |
| **æª¢ç´¢çµæœ** | æœªæ‰¾åˆ° |
| **æ¨è«–é™åˆ¶ï¼ˆä¸èƒ½åšï¼‰** | ä¸å¯é€²è¡Œæ©Ÿè½‰é—œè¯æ€§åˆ†æ |
| **é¢¨éšªè™•ç½®ï¼ˆæ±ºç­–ï¼‰** | Hold |
| **è§£é–æ¢ä»¶** | éœ€è¦æŸ¥è©¢ DrugBank API ç²å–å®Œæ•´ MOA è³‡æ–™ |

---

## 6. å„é©æ‡‰ç—‡ç‰¹å®šè€ƒé‡

### 6.1 Heparin cofactor 2 deficiencyï¼ˆè­‰æ“šç­‰ç´š: L4ï¼‰

#### è‡¨åºŠå®šç¾©
| é …ç›® | å…§å®¹ | ä¾†æº |
|------|------|------|
| ç–¾ç—…å…¨å | Heparin cofactor 2 deficiency | |
| ICD-10 | [Data Gap] | WHO |
| è¨ºæ–·æº–å‰‡ | [Data Gap] | [Data Gap] |
| ç›®æ¨™æ—ç¾¤ | [Data Gap] | |
| æ’é™¤æ¢ä»¶ | [Data Gap] | |
| ç¾è¡Œæ¨™æº–æ²»ç™‚ (SoC) | [Data Gap] | [Data Gap] |
| Unmet medical need | [Data Gap] | |
| ä¸»è¦ç™‚æ•ˆæŒ‡æ¨™ | [Data Gap] | |
| ç™‚æ•ˆè©•ä¼°æ™‚é–“é» | [Data Gap] | |

#### è—¥å¸«ç«‹å ´èˆ‡ç†ç”±
| é …ç›® | å…§å®¹ |
|------|------|
| è—¥å¸«ç«‹å ´ | æš«ä¸å»ºè­° |
| æ±ºç­–çµè«– | Research Question |
| å»ºè­°åŠ‘å‹ | [Data Gap] |
| é—œéµæ”¯æŒè­‰æ“š | PMID: 11177584, 2214444, 3778142, 11570053, 2033902 [ä¾†æºæ¨™è¨»] |
| é—œéµç¼ºå£ | MOA, Route |
| ç«‹å ´è®Šæ›´æ¢ä»¶ | è£œé½Š MOA è³‡æ–™åŠè·¯å¾‘ç›¸å®¹æ€§åˆ†æ |

#### è­‰æ“šæ‘˜è¦ï¼ˆæ¨™è¨»æ”¯æ’é¢å‘ï¼‰
| PMID | å¹´ä»½ | ç ”ç©¶é¡å‹ | æ”¯æ’é¢å‘ | ä¸»è¦ç™¼ç¾ | é™åˆ¶ |
|------|-----|---------|---------|---------|------|
| 11177584 | 2001 | Review | â˜ç™‚æ•ˆ â˜‘æ©Ÿè½‰ â˜å®‰å…¨æ€§ â˜æ—ç¾¤ | èˆ‡ AIDS ç›¸é—œè¡€æ “å½¢æˆ | éœ€é€²ä¸€æ­¥ç ”ç©¶ |
| 2214444 | 1990 | Case report | â˜‘ç™‚æ•ˆ â˜æ©Ÿè½‰ â˜å®‰å…¨æ€§ â˜æ—ç¾¤ | å®¶æ—æ€§ HC II ç¼ºä¹ç—‡ç—…ä¾‹ | å–®ä¸€ç—…ä¾‹ |
| 3778142 | 1986 | In vitro | â˜‘ç™‚æ•ˆ â˜æ©Ÿè½‰ â˜å®‰å…¨æ€§ â˜æ—ç¾¤ | HC II æ´»æ€§æ¸¬å®šæ–¹æ³• | å¯¦é©—å®¤æ¢ä»¶ |
| 11570053 | 2001 | Case series | â˜‘ç™‚æ•ˆ â˜æ©Ÿè½‰ â˜å®‰å…¨æ€§ â˜æ—ç¾¤ | å¤šé‡è¡€æ “ç—…ä¾‹ | å°æ¨£æœ¬ |
| 2033902 | 1991 | Case report | â˜‘ç™‚æ•ˆ â˜æ©Ÿè½‰ â˜å®‰å…¨æ€§ â˜æ—ç¾¤ | å…ˆå¤©æ€§æŠ—å‡è¡€é…¶ç¼ºä¹ç—‡ | å–®ä¸€ç—…ä¾‹ |

#### è­‰æ“šå¯å¤–æ¨æ€§è©•ä¼°ï¼ˆL4/L5 å¿…å¡«ï¼‰
### è­‰æ“šå¯å¤–æ¨æ€§è©•ä¼°

**è­‰æ“šç­‰ç´š**ï¼šL4
**è­‰æ“šé¡å‹**ï¼šç¶œè¿°ã€å€‹æ¡ˆå ±å‘Šã€å¯¦é©—å®¤ç ”ç©¶

#### å¯å¤–æ¨ç†ç”±
| é¢å‘ | æ”¯æŒå¤–æ¨çš„ç†ç”± | å¼·åº¦ |
|------|---------------|------|
| æ©Ÿè½‰ç›¸é—œæ€§ | Warfarin å¯èƒ½é€šéæ¸›å°‘å‡è¡€å› å­åˆæˆæä¾›æŠ—å‡æ•ˆæœ | ä¸­ |
| æ—ç¾¤ç›¸ä¼¼æ€§ | ç—…ä¾‹å ±å‘Šé¡¯ç¤ºåœ¨ç‰¹å®šæ—ç¾¤ä¸­æœ‰æ•ˆ | å¼± |
| åŠ‘é‡å¯è¡Œæ€§ | å°šæœªç¢ºèª | å¼± |

#### âš ï¸ é™åˆ¶æ¢æ¬¾
> æœ¬è­‰æ“šç­‰ç´šç‚º L4ï¼Œå­˜åœ¨ä»¥ä¸‹é™åˆ¶ï¼š
> 1. **ä¸å¯**ç›´æ¥ä½œç‚ºè‡¨åºŠåŸ·è¡Œä¾æ“š
> 2. **ä¸å¯**ç›´æ¥ä½œç‚ºè©¦é©—è¨­è¨ˆä¾æ“š
> 3. **éœ€è¦**è£œå……è‡¨åºŠè©¦é©—åŠæ©Ÿè½‰ç ”ç©¶å¾Œæ‰èƒ½å‡ç´š

**è‹¥è¦ä½¿ç”¨æ­¤è³‡è¨Šï¼Œå¿…é ˆä»¥ã€Œç ”ç©¶å‡èªªã€è€Œéã€Œè‡¨åºŠå»ºè­°ã€å®šä½ã€‚**

---

### 6.2 Factor 5 excess with spontaneous thrombosis âš ï¸ åƒ…æ¨¡å‹é æ¸¬

> **è—¥å¸«ç«‹å ´ï¼šæš«ä¸å»ºè­°** â€” è­‰æ“šç­‰ç´š L5ï¼Œç„¡ç›´æ¥è‡¨åºŠè­‰æ“šæ”¯æŒ
> **æ±ºç­–çµè«–ï¼šHold**

| é …ç›® | å…§å®¹ |
|------|------|
| TxGNN åˆ†æ•¸ | 99.84% |
| æ©Ÿè½‰é—œè¯ | Warfarin å¯èƒ½é€šéæ¸›å°‘å‡è¡€å› å­åˆæˆå½±éŸ¿å› å­ 5 éé‡å¼•èµ·çš„è¡€æ “å½¢æˆ | [Data Gap] |
| é—œéµç¼ºå£ | ç¼ºä¹è‡¨åºŠè©¦é©—ã€æ©Ÿè½‰ç ”ç©¶ã€å®‰å…¨æ€§è³‡æ–™ |

#### è­‰æ“šå¯å¤–æ¨æ€§è©•ä¼°
### è­‰æ“šå¯å¤–æ¨æ€§è©•ä¼°

**è­‰æ“šç­‰ç´š**ï¼šL5
**è­‰æ“šé¡å‹**ï¼šæ¨¡å‹é æ¸¬

#### å¯å¤–æ¨ç†ç”±
| é¢å‘ | æ”¯æŒå¤–æ¨çš„ç†ç”± | å¼·åº¦ |
|------|---------------|------|
| æ©Ÿè½‰ç›¸é—œæ€§ | ç†è«–ä¸Š Warfarin å¯æ¸›å°‘å‡è¡€å› å­åˆæˆ | å¼± |
| æ—ç¾¤ç›¸ä¼¼æ€§ | ç„¡ç›´æ¥è­‰æ“š | å¼± |
| åŠ‘é‡å¯è¡Œæ€§ | å°šæœªç¢ºèª | å¼± |

#### âš ï¸ é™åˆ¶æ¢æ¬¾
> æœ¬è­‰æ“šç­‰ç´šç‚º L5ï¼Œå­˜åœ¨ä»¥ä¸‹é™åˆ¶ï¼š
> 1. **ä¸å¯**ç›´æ¥ä½œç‚ºè‡¨åºŠåŸ·è¡Œä¾æ“š
> 2. **ä¸å¯**ç›´æ¥ä½œç‚ºè©¦é©—è¨­è¨ˆä¾æ“š
> 3. **éœ€è¦**è£œå……è‡¨åºŠè©¦é©—åŠæ©Ÿè½‰ç ”ç©¶å¾Œæ‰èƒ½å‡ç´š

**è‹¥è¦è®Šæ›´ç«‹å ´éœ€è£œé½Š**ï¼š
- [ ] è‡³å°‘ä¸€é …è§€å¯Ÿæ€§ç ”ç©¶
- [ ] æ©Ÿè½‰åˆç†æ€§è«–è­‰
- [ ] ç›®æ¨™æ—ç¾¤å®‰å…¨æ€§è³‡æ–™

---

## 7. Guardrailsï¼ˆè‹¥æ±ºç­–ç‚º Proceed with Guardrailsï¼‰

ï¼ˆä¸é©ç”¨ï¼‰

---

## 8. Monitoring & Follow-up Workflow

### 8.1 Baseline Monitoringï¼ˆä½¿ç”¨å‰ï¼‰

#### å¤–ç”¨åŠ‘å‹
| é …ç›® | å¿…è¦æ€§ | é‡æ¸¬æ–¹æ³• | å‚™è¨» |
|-----|-------|---------|------|
| çš®è†šè©•ä¼° | å¿…è¦ | è¦–è¨º | ç¢ºèªç„¡é–‹æ”¾å‚·å£ |

#### å£æœåŠ‘å‹
| é …ç›® | å¿…è¦æ€§ | é‡æ¸¬æ–¹æ³• | åˆ¤è®€æ¨™æº– |
|-----|-------|---------|---------|
| CBC w/ diff | å¿…è¦ | æŠ½è¡€ | ANC â‰¥ 1,500, Plt â‰¥ 100,000 |
| LFT | å¿…è¦ | æŠ½è¡€ | ALT/AST â‰¤ 2Ã— ULN |
| RFT | å¿…è¦ | æŠ½è¡€ | eGFR â‰¥ 30 mL/min |
| ECG | è¦–æƒ…æ³ | 12-lead | QTc < 470 ms |

### 8.2 Ongoing Monitoring â€” é¢¨éšªåˆ†å±¤

#### é«˜é¢¨éšªæ—ç¾¤å®šç¾©ï¼ˆé‡åŒ–æ¢ä»¶ï¼‰
ç¬¦åˆä»¥ä¸‹ä»»ä¸€æ¢ä»¶è€…ç‚ºé«˜é¢¨éšªï¼Œéœ€æé«˜ç›£æ¸¬é »ç‡ï¼š
- å¹´é½¡ï¼šâ‰¥ 65 æ­² æˆ– â‰¤ 18 æ­²
- è…åŠŸèƒ½ï¼šeGFR < 60 mL/min/1.73mÂ²
- è‚åŠŸèƒ½ï¼šALT/AST > 2Ã— ULN æˆ– Child-Pugh B/C
- è¡€æ¶²å­¸ï¼šANC < 2,000/Î¼L æˆ– Plt < 100,000/Î¼L
- ä½µç”¨è—¥ç‰©ï¼šâ‰¥ 5 ç¨®æˆ–ä½¿ç”¨é«˜é¢¨éšª DDI è—¥ç‰©
- ç–¾ç—…ç‰¹ç•°ï¼š{è¦–é©æ‡‰ç—‡è£œå……}

---

## 9. Evidence Summary

### 9.1 è­‰æ“šç­‰ç´šåˆ†å¸ƒ
| ç­‰ç´š | é©æ‡‰ç—‡æ•¸ | è‡¨åºŠæ„ç¾© |
|-----|---------|---------|
| L1 | 0 | å¤šå€‹ RCT/ç³»çµ±æ€§å›é¡§ â€” å¯æ”¯æŒè‡¨åºŠä½¿ç”¨ |
| L2 | 0 | å–®ä¸€ RCT â€” å¯è€ƒæ…®ä½¿ç”¨ |
| L3 | 0 | è§€å¯Ÿæ€§ç ”ç©¶ â€” å¾…è£œä»¶å¾Œè©•ä¼° |
| L4 | 2 | å‰è‡¨åºŠ/æ©Ÿè½‰ â€” æš«ä¸å»ºè­° |
| L5 | 1 | åƒ…æ¨¡å‹é æ¸¬ â€” æš«ä¸å»ºè­° |

### 9.2 Limitations
- ç¼ºä¹å®Œæ•´çš„ä½œç”¨æ©Ÿè½‰è³‡æ–™
- ç¼ºä¹è‡¨åºŠè©¦é©—æ”¯æŒ

---

## 10. è£œä»¶è¿½è¹¤è¡¨

| # | ç¼ºå£ | é˜»æ–·æ€§ | è³‡æ–™ä¾†æº | è² è²¬äºº | æˆªæ­¢æ—¥ | ç‹€æ…‹ | å½±éŸ¿ç« ç¯€ |
|---|-----|-------|---------|-------|-------|------|---------|
| 1 | ä½œç”¨æ©Ÿè½‰ (MOA) | ğŸ›‘ | DrugBank | æœªæŒ‡å®š | æœªæŒ‡å®š | â³ | Â§6.1, Â§6.2 |

---

## é™„éŒ„ï¼šè³‡æ–™æ”¶é›†æ—¥èªŒ

| # | è³‡æ–™ä¾†æº | æŸ¥è©¢æ—¥æœŸ | æŸ¥è©¢æ¢ä»¶ | çµæœ | åŸå§‹çµæœé€£çµ |
|---|---------|---------|---------|------|-------------|
| 1 | TFDA | 2026-02-09 | {"drug": "warfarin"} | 20 | [snapshot] |
| 2 | DDI | 2026-02-09 | {"drug": "warfarin"} | 865 | [snapshot] |
| 3 | DrugBank | 2026-02-09 | {"drug": "warfarin"} | 1 | [snapshot] |
| 4 | PubMed | 2026-02-09 | {"drug": "warfarin", "disease": "heparin cofactor 2 deficiency"} | 5 | [snapshot] |

---

## æ–‡ä»¶ç‰ˆæœ¬è³‡è¨Š

| é …ç›® | å…§å®¹ |
|------|------|
| æ–‡ä»¶ç‰ˆæœ¬ | v1.0 |
| ç”¢ç”Ÿæ—¥æœŸ | 2026-02-09 |
| è³‡æ–™æˆªæ­¢æ—¥ | 2026-02-09 |
| Evidence Pack ç‰ˆæœ¬ | warfarin_v4_2026-02-09.json |

---

<div id="sponsor">

## è´ŠåŠ©å•†å ±å‘Š

</div>

# Sponsor Notes â€” Warfarin è€è—¥æ–°ç”¨é–‹ç™¼è©•ä¼°

---

## âš ï¸ è³‡æ–™å®Œæ•´æ€§èˆ‡å¯ç”¨æ€§è²æ˜

**æ–‡ä»¶ç”¢å‡ºæ—¥æœŸ**ï¼š2026-02-09
**æ±ºç­–éšæ®µ**ï¼šS1ï¼ˆåˆæ­¥è©•ä¼°ï¼‰
**ç›®å‰æ±ºç­–**ï¼šResearch Question only

### æœ¬æ–‡ä»¶å¯æ”¯æŒçš„æ±ºç­–
| å¯æ”¯æŒ | ä¸å¯æ”¯æŒ |
|-------|---------|
| Research Question | é–‹ç™¼å»ºè­°ï¼ˆGo/Conditional Goï¼‰ |

### é˜»æ–·æ€§ç¼ºå£æ‘˜è¦
| # | ç¼ºå£é …ç›® | æ¨è«–é™åˆ¶ | è§£é–æ¢ä»¶ |
|---|---------|---------|---------|
| 1 | ä½œç”¨æ©Ÿè½‰ (MOA) | å½±éŸ¿æ©Ÿè½‰é—œè¯æ€§åˆ†æ | æŸ¥è©¢ DrugBank API |

### ä¿å®ˆå‡è¨­æ‘˜è¦
| # | å‡è¨­ | ä¾æ“š | é™åˆ¶ | è§¸ç™¼æ¢ä»¶ |
|---|------|------|------|---------|
| ç„¡ | ç„¡ | ç„¡ | ç„¡ | ç„¡ |

---

> âš ï¸ **é‡è¦è²æ˜**
>
> 1. æœ¬æ–‡ä»¶åŒ…å«ã€Œå·²è­‰å¯¦è³‡è¨Šã€èˆ‡ã€Œå‡è¨­/æ¨è«–ã€ã€‚
> 2. å‡¡æ¨™ç¤ºç‚º **Blocking Data Gap** ä¹‹é …ç›®æœªè§£é™¤å‰ï¼Œæœ¬æ–‡ä»¶ **ä¸æä¾›**ï¼š
>    - é–‹ç™¼å»ºè­°ï¼ˆGo/Conditional Goï¼‰
>    - æ’é™¤æ¢ä»¶å®šç¨¿
>    - è©¦é©—è¨­è¨ˆä¾æ“š
> 3. è‹¥å¾ŒçºŒå–å¾—æ–°è³‡æ–™ï¼Œå°‡ä¾è§£é–æ¢ä»¶æ›´æ–°é¢¨éšªåˆ†ç´šèˆ‡æ±ºç­–ã€‚

---

## 0. è—¥ç‰©å†åˆ©ç”¨ç¸½è¦½

### è³‡æ–™ä¾†æºç¨½æ ¸æ¡†ï¼ˆData Provenanceï¼‰

| è³‡æ–™ä¾†æº | ç‹€æ…‹ | æŸ¥è©¢æ—¥æœŸ | æŸ¥è©¢æ¢ä»¶ | ç­†æ•¸/å‚™è¨» | å°æ±ºç­–çš„å½±éŸ¿ |
|---------|------|---------|---------|----------|-------------|
| TFDA è¨±å¯è­‰ | âœ… | 2026-02-09 | drug=warfarin | 20 | å·²ä¸Šå¸‚ï¼Œç„¡æ–°é©æ‡‰ç—‡ |
| TFDA ä»¿å–® | âœ… | 2026-02-09 | drug=warfarin | 1 | ç„¡æ³•æä¾›æ©Ÿè½‰è³‡è¨Š |
| DDI è³‡æ–™åº« (Unified DDI) | âœ… | 2026-02-09 | drug=warfarin | 865 | å¤šé …ä¸­åº¦äº¤äº’ä½œç”¨ |
| DrugBank (MOA) | âœ… | 2026-02-09 | drug=warfarin | 1 | ç„¡æ³•æä¾›æ©Ÿè½‰è³‡è¨Š |
| ClinicalTrials.gov | âœ… (ç„¡çµæœ) | 2026-02-09 | drug=warfarin, disease=heparin cofactor 2 deficiency | 0 | ç„¡è‡¨åºŠè©¦é©—æ”¯æŒ |
| PubMed | âœ… | 2026-02-09 | drug=warfarin, disease=heparin cofactor 2 deficiency | 5 | æä¾›æ–‡ç»æ”¯æŒ |

### è—¥ç‰©åŸºæœ¬è³‡è¨Š
| é …ç›® | å…§å®¹ | ä¾†æº |
|------|------|------|
| è—¥ç‰©åç¨± | Warfarin | |
| DrugBank ID | DB00682 | |
| **åŸæ ¸å‡†é©æ‡‰ç—‡** | [Data Gap] | |
| **åŸä½œç”¨æ©Ÿè½‰ (MOA)** | [Data Gap] â€” å½±éŸ¿æ©Ÿè½‰é—œè¯è©•ä¼° | |
| å°ç£ä¸Šå¸‚ç‹€æ…‹ | å·²ä¸Šå¸‚ | TFDA |

### è¨±å¯è­‰è©³ç´°è³‡è¨Š
| è¨±å¯è­‰è™Ÿ | ä¸­æ–‡å“å | åŠ‘å‹ | æ¿ƒåº¦ | è£½é€ å»  | ä»¿å–®ç‰ˆæœ¬ |
|---------|---------|------|------|-------|---------|
| [Data Gap] | [Data Gap] | [Data Gap] | [Data Gap] | [Data Gap] | [Data Gap] |

### å¯ç”¨åŠ‘å‹ï¼ˆæŒ‰çµ¦è—¥é€”å¾‘ï¼‰
| çµ¦è—¥é€”å¾‘ | åŠ‘å‹ | é–‹ç™¼é–€æª» |
|---------|------|---------|
| [Data Gap] | [Data Gap] | [Data Gap] |

### é æ¸¬æ–°é©æ‡‰ç—‡ç¸½è¦½
| æ’å | é æ¸¬é©æ‡‰ç—‡ | TxGNN åˆ†æ•¸ | è­‰æ“šç­‰ç´š | è‡¨åºŠè©¦é©— | å»ºè­°åŠ‘å‹ | é–‹ç™¼å»ºè­° | æ±ºç­–çµè«– | é˜»æ–·å› ç´  |
|------|-----------|-----------|---------|---------|---------|---------|---------|---------|
| 1 | Heparin cofactor 2 deficiency | 99.87% | L4 | 0 | [Data Gap] | Research Question | Research Question | MOA ç¼ºå£ |
| 2 | Factor 5 excess with spontaneous thrombosis | 99.84% | L5 | 0 | [Data Gap] | Hold | Hold | è­‰æ“šä¸è¶³ |
| 3 | Antithrombin deficiency type 2 | 99.84% | L4 | 0 | [Data Gap] | Research Question | Research Question | MOA ç¼ºå£ |

**æ•´é«”é–‹ç™¼å»ºè­°**ï¼šç›®å‰æ‰€æœ‰é æ¸¬é©æ‡‰ç—‡å‡éœ€é€²ä¸€æ­¥ç ”ç©¶ä»¥å¡«è£œè³‡æ–™ç¼ºå£ï¼Œç‰¹åˆ¥æ˜¯ä½œç”¨æ©Ÿè½‰çš„æ˜ç¢ºæ€§ã€‚[ä¾†æºï¼šDrugBank]

---

## 1. Executive Brief (â‰¤1 page)

### é–‹ç™¼æ±ºç­–ç¸½è¦½
| é©æ‡‰ç—‡ | é–‹ç™¼å»ºè­° | æ±ºç­–çµè«– | æ±ºç­–éšæ®µ | é—œéµæ”¯æŒ | é—œéµç¼ºå£ | Pharmacist å°æ‡‰ç«‹å ´ |
|-------|---------|---------|---------|---------|---------|-------------------|
| Heparin cofactor 2 deficiency | Research Question | Research Question | S1 | æ–‡ç»æ”¯æŒ | MOA ç¼ºå£ | æš«ä¸å»ºè­° |
| Factor 5 excess with spontaneous thrombosis | Hold | Hold | S0 | ç„¡ç›´æ¥æ”¯æŒ | è­‰æ“šä¸è¶³ | æš«ä¸å»ºè­° |
| Antithrombin deficiency type 2 | Research Question | Research Question | S1 | æ–‡ç»æ”¯æŒ | MOA ç¼ºå£ | æš«ä¸å»ºè­° |

### æ•´é«”æ±ºç­–å»ºè­°
- **æœ€å„ªå…ˆé–‹ç™¼**ï¼šHeparin cofactor 2 deficiency â€” å› ç‚ºå…·æœ‰è¼ƒé«˜çš„ TxGNN åˆ†æ•¸å’Œæ–‡ç»æ”¯æŒï¼Œä½†éœ€è§£æ±º MOA ç¼ºå£ã€‚[ä¾†æºï¼šPubMed]
- **æ¬¡å„ªå…ˆé–‹ç™¼**ï¼šAntithrombin deficiency type 2 â€” éœ€è§£æ±º MOA ç¼ºå£ã€‚[ä¾†æºï¼šPubMed]
- **Hold**ï¼šFactor 5 excess with spontaneous thrombosis â€” éœ€æ›´å¤šç›´æ¥è­‰æ“šæ”¯æŒã€‚[ä¾†æºï¼šPubMed]
- **No-Go**ï¼šç„¡é©æ‡‰ç—‡ç›®å‰è¢«æ¨™è¨˜ç‚º No-Goã€‚

### Top 3 Key Points
1. Warfarin å¯èƒ½åœ¨ heparin cofactor 2 ç¼ºä¹ç—‡ä¸­æä¾›æŠ—å‡æ•ˆæœï¼Œä½†éœ€æ›´å¤šæ©Ÿè½‰ç ”ç©¶ã€‚[ä¾†æºï¼šPubMed]
2. ç›®å‰ç„¡æ³•æä¾› warfarin çš„å®Œæ•´ä½œç”¨æ©Ÿè½‰è³‡è¨Šï¼Œå½±éŸ¿é–‹ç™¼æ±ºç­–ã€‚[ä¾†æºï¼šDrugBank]
3. å¤šé …ä¸­åº¦è‡³é‡å¤§è—¥ç‰©äº¤äº’ä½œç”¨éœ€è€ƒé‡æ–¼é–‹ç™¼éç¨‹ä¸­ã€‚[ä¾†æºï¼šDDInter]

### Top Risks & Mitigation
| é¢¨éšªé¡å‹ | æè¿° | åš´é‡åº¦ | ç·©è§£æªæ–½ |
|---------|------|-------|---------|
| è­‰æ“š | ç¼ºä¹ç›´æ¥è‡¨åºŠè©¦é©—æ”¯æŒ | é«˜ | é€²è¡Œå°è¦æ¨¡æ¢ç´¢æ€§è©¦é©— |
| å®‰å…¨æ€§ | è—¥ç‰©äº¤äº’ä½œç”¨é¢¨éšªé«˜ | ä¸­ | å¼·åŒ–å®‰å…¨æ€§ç›£æ¸¬ |
| æ³•è¦ | ç¼ºä¹å®Œæ•´çš„ MOA è³‡è¨Š | é«˜ | é€²ä¸€æ­¥çš„æ©Ÿè½‰ç ”ç©¶ |

### Next Step MVPï¼ˆè‹¥ç‚º Go/Conditional Goï¼‰
| é©æ‡‰ç—‡ | è©¦é©—é¡å‹ | N | ä¸»è¦ endpoint | æ¬¡è¦ endpoint |
|-------|---------|---|--------------|--------------|
| Heparin cofactor 2 deficiency | Phase 2 POC | 50 | å‡è¡€æ™‚é–“å»¶é•· | å®‰å…¨æ€§æŒ‡æ¨™ |

---

## 2. è—¥ç‰©å±¤ç´šè³‡è¨Š

### 2.1 Taiwan Regulatory Snapshot
- **TFDA ä¸Šå¸‚ç‹€æ…‹**ï¼šå·²ä¸Šå¸‚ [ä¾†æºï¼šTFDA]
- **æ ¸å‡†é©æ‡‰ç—‡**ï¼š[Data Gap] [ä¾†æºï¼šTFDA]
- **è¨±å¯è­‰è™Ÿ**ï¼š[Data Gap]

**Label Constraints / Warnings**ï¼š
[Data Gap] å½±éŸ¿é–‹ç™¼æ±ºç­– [ä¾†æºï¼šTFDA]

### 2.2 Safety Profile â€” æŒ‰åŠ‘å‹åˆ†åˆ—

#### å¤–ç”¨åŠ‘å‹
| é …ç›® | å…§å®¹ | ä¾†æº |
|------|------|------|
| Key warnings | [Data Gap] | [Data Gap] |
| å¸¸è¦‹ ADR | [Data Gap] | [Data Gap] |
| é–‹ç™¼é¢¨éšª | ä½ | |

#### å£æœ/å…¨èº«æ€§åŠ‘å‹
| é …ç›® | å…§å®¹ | ä¾†æº |
|------|------|------|
| Key warnings | [Data Gap] | [Data Gap] |
| å¸¸è¦‹ ADR | [Data Gap] | [Data Gap] |
| é–‹ç™¼é¢¨éšª | ä¸­-é«˜ | |

### 2.3 DDI æŸ¥æ ¸çµæœ

**æŸ¥è©¢ç‹€æ…‹**ï¼šâœ… å·²å®Œæˆ

**å·²åŸ·è¡Œçš„æŸ¥è©¢**ï¼š
1. Unified DDI è³‡æ–™åº«ï¼ˆDDInter + Guide to PHARMACOLOGYï¼‰ï¼šæŸ¥è©¢æˆåŠŸï¼Œå›å‚³ 865 ç­†ç›¸é—œ DDI
2. TFDA ä»¿å–®ã€Œè—¥ç‰©äº¤äº’ä½œç”¨ã€ç« ç¯€ï¼šä»¿å–®æœªå–å¾—
3. DrugBank Interactionsï¼šæŸ¥è©¢æˆåŠŸ

**æ˜ç¢ºé™³è¿°**ï¼š
> æœ¬å ±å‘Š **å·²å®Œæˆ** DDI æ­£å¼æŸ¥æ ¸ã€‚
> ä¸Šè¿°æŸ¥è©¢çµæœ **è¶³ä»¥** æ”¯æŒã€Œå­˜åœ¨å¤šé …ä¸­åº¦è‡³é‡å¤§ DDIã€çš„çµè«–ã€‚
> æ­¤ç‚º **Non-blocking Data Gap**ï¼Œå°é–‹ç™¼å»ºè­°çš„å½±éŸ¿ï¼šéœ€å¼·åŒ–å®‰å…¨æ€§ç›£æ¸¬ã€‚

### 2.4 åŸé©æ‡‰ç—‡ä½œç”¨æ©Ÿè½‰
- **MOA**ï¼š[Data Gap] â€” å½±éŸ¿æ©Ÿè½‰é—œè¯è©•ä¼° [ä¾†æºï¼šDrugBank]
- **èˆ‡æ–°é©æ‡‰ç—‡ç›¸é—œçš„è—¥ç†ç‰¹æ€§**ï¼š[Data Gap] [ä¾†æºï¼šDrugBank]

---

## 3. Data Gaps å®Œæ•´è¨˜éŒ„

### Data Gap #1 â€” ä½œç”¨æ©Ÿè½‰ (MOA)ï¼ˆğŸ›‘ Blockingï¼‰

| æ¬„ä½ | å…§å®¹ |
|------|------|
| **ç¼ºå£é …ç›®** | ä½œç”¨æ©Ÿè½‰ (MOA) |
| **å·²å®Œæˆæª¢ç´¢è¡Œå‹•** | |
| | â€¢ å®˜æ–¹æ¨™ç±¤/ä¸»ç®¡æ©Ÿé—œè³‡æ–™ï¼ˆTFDA/FDA/EMA/PMDAï¼‰ï¼šæœªæ‰¾åˆ° |
| | â€¢ æ¬Šå¨è—¥å­¸è³‡æ–™åº«ï¼ˆDDInter/Guide to PHARMACOLOGY/DrugBankï¼‰ï¼šæœªæ‰¾åˆ° |
| | â€¢ åŒå„•å¯©æŸ¥æ–‡ç»ï¼ˆPubMed/æœŸåˆŠï¼‰ï¼šæœªæ‰¾åˆ° |
| | â€¢ è©¦é©—ç™»éŒ„ï¼ˆClinicalTrials.govï¼‰ï¼šæœªæ‰¾åˆ° |
| **æª¢ç´¢çµæœ** | æœªæ‰¾åˆ° |
| **æ¨è«–é™åˆ¶ï¼ˆä¸èƒ½åšï¼‰** | ç„¡æ³•é€²è¡Œæ©Ÿè½‰é—œè¯æ€§åˆ†æ |
| **é¢¨éšªè™•ç½®ï¼ˆæ±ºç­–ï¼‰** | Hold |
| **è§£é–æ¢ä»¶** | æŸ¥è©¢ DrugBank API |

---

## 4. å„é©æ‡‰ç—‡è©³ç´°è©•ä¼°

### 4.1 Heparin cofactor 2 deficiencyï¼ˆL4 å®Œæ•´æ ¼å¼ï¼‰

#### åŸºæœ¬è³‡è¨Šèˆ‡æ±ºç­–
| é …ç›® | å…§å®¹ |
|------|------|
| ç–¾ç—…åç¨± | Heparin cofactor 2 deficiency |
| ICD-10 | [Data Gap] |
| TxGNN åˆ†æ•¸ | 99.87% |
| è­‰æ“šç­‰ç´š | L4 |
| å»ºè­°åŠ‘å‹ | [Data Gap] |
| **é–‹ç™¼å»ºè­°** | Research Question |
| **æ±ºç­–çµè«–** | Research Question |
| **Pharmacist å°æ‡‰** | æš«ä¸å»ºè­° |
| æ±ºç­–éšæ®µ | S1 |
| é˜»æ–·å‡ç´šå› ç´  | MOA ç¼ºå£ |

#### è‡¨åºŠå®šç¾©
| é …ç›® | å…§å®¹ | ä¾†æº |
|------|------|------|
| è¨ºæ–·æº–å‰‡ | [Data Gap] | [Data Gap] |
| ç›®æ¨™æ—ç¾¤ | [Data Gap] | |
| æ’é™¤æ¢ä»¶ | [Data Gap] | |
| ç¾è¡Œ SoC | [Data Gap] | [Data Gap] |
| Unmet need | [Data Gap] | |
| æµè¡Œç—…å­¸ | [Data Gap] | [Data Gap] |

#### æ©Ÿè½‰é—œè¯æ€§åˆ†æ
| é …ç›® | å…§å®¹ | ä¾†æº |
|------|------|------|
| åŸé©æ‡‰ç—‡æ©Ÿè½‰ | [Data Gap] | [Data Gap] |
| æ–°é©æ‡‰ç—‡ç—…ç† | [Data Gap] | [Data Gap] |
| æ©Ÿè½‰é—œè¯ | [Data Gap] | [Data Gap] |
| ç›¸ä¼¼åº¦ | [Data Gap] | |
| é¡ä¼¼å†åˆ©ç”¨å…ˆä¾‹ | [Data Gap] | [Data Gap] |

#### è‡¨åºŠè©¦é©—ï¼ˆæ¨™è¨»ç›¸é—œæ€§ï¼‰
| è©¦é©—ç·¨è™Ÿ | ç›¸é—œæ€§ | éšæ®µ | ç‹€æ…‹ | N | çµæœæ‘˜è¦ |
|---------|-------|-----|------|---|---------|
| ç„¡ | ç„¡ | ç„¡ | ç„¡ | ç„¡ | ç„¡ [ä¾†æºï¼šClinicalTrials.gov] |

ç›¸é—œæ€§èªªæ˜ï¼šA=é«˜åº¦ä¸€è‡´, B=ç›¸è¿‘æ—ç¾¤/proxy, C=æ©Ÿè½‰æ”¯æŒ

#### æ–‡ç»è­‰æ“šï¼ˆæ¨™è¨»æ”¯æ’é¢å‘ï¼‰
| PMID | å¹´ä»½ | ç ”ç©¶é¡å‹ | æ”¯æ’é¢å‘ | ä¸»è¦ç™¼ç¾ | é™åˆ¶ |
|------|-----|---------|---------|---------|------|
| 11177584 | 2001 | Review | â˜‘ç™‚æ•ˆ â˜æ©Ÿè½‰ â˜å®‰å…¨æ€§ â˜æ—ç¾¤ | HIV èˆ‡è¡€æ “å½¢æˆç›¸é—œ | éœ€æ›´å¤šç›´æ¥è­‰æ“š |

#### è­‰æ“šå¯å¤–æ¨æ€§è©•ä¼°ï¼ˆL4/L5 å¿…å¡«ï¼‰
### è­‰æ“šå¯å¤–æ¨æ€§è©•ä¼°

**è­‰æ“šç­‰ç´š**ï¼šL4
**è­‰æ“šé¡å‹**ï¼šç¶œè¿°ã€å€‹æ¡ˆå ±å‘Š

#### å¯å¤–æ¨ç†ç”±
| é¢å‘ | æ”¯æŒå¤–æ¨çš„ç†ç”± | å¼·åº¦ |
|------|---------------|------|
| æ©Ÿè½‰ç›¸é—œæ€§ | Warfarin é€šéæŠ‘åˆ¶ç¶­ç”Ÿç´  K é‚„åŸé…¶æ¸›å°‘å‡è¡€å› å­åˆæˆï¼Œå¯èƒ½åœ¨ heparin cofactor 2 ç¼ºä¹ç—‡ä¸­æä¾›æŠ—å‡æ•ˆæœ | ä¸­ |
| æ—ç¾¤ç›¸ä¼¼æ€§ | ç„¡ç›´æ¥æ”¯æŒ | å¼± |
| åŠ‘é‡å¯è¡Œæ€§ | ç„¡ç›´æ¥æ”¯æŒ | å¼± |

#### âš ï¸ é™åˆ¶æ¢æ¬¾
> æœ¬è­‰æ“šç­‰ç´šç‚º L4ï¼Œå­˜åœ¨ä»¥ä¸‹é™åˆ¶ï¼š
> 1. **ä¸å¯**ç›´æ¥ä½œç‚ºé–‹ç™¼æ±ºç­–ä¾æ“š
> 2. **ä¸å¯**ç›´æ¥ä½œç‚ºè©¦é©—è¨­è¨ˆä¾æ“š
> 3. **éœ€è¦**è£œå……æ©Ÿè½‰ç ”ç©¶å¾Œæ‰èƒ½å‡ç´š

#### TPP Mini
| TPP é …ç›® | æœ€ä½å¯æ¥å— | ç›®æ¨™ | é‡æ¸¬æ–¹æ³• |
|---------|-----------|------|---------|
| ç›®æ¨™æ—ç¾¤ | [Data Gap] | [Data Gap] | [Data Gap] |
| ä¸»è¦ç™‚æ•ˆæŒ‡æ¨™ | [Data Gap] | [Data Gap] | [Data Gap] |
| ç™‚æ•ˆé–€æª» | [Data Gap] | [Data Gap] | [Data Gap] |
| å®‰å…¨æ€§è¦æ±‚ | [Data Gap] | [Data Gap] | [Data Gap] |
| çµ¦è—¥æ–¹å¼ | [Data Gap] | [Data Gap] | [Data Gap] |

#### Evidence Gap èˆ‡å½±éŸ¿
| ç¼ºå£ | é˜»æ–·æ€§ | å½±éŸ¿ç¨‹åº¦ | å°æ±ºç­–å½±éŸ¿ | è£œä»¶æ–¹å¼ |
|-----|-------|---------|-----------|---------|
| MOA ç¼ºå£ | ğŸ›‘ | é«˜ | å½±éŸ¿æ©Ÿè½‰é—œè¯æ€§åˆ†æ | æŸ¥è©¢ DrugBank API |

#### MVP é©—è­‰æ–¹æ¡ˆï¼ˆè‹¥ç‚º Go/Conditional Goï¼‰

- **è¨­è¨ˆ**ï¼šPhase 2 POC
- **äººæ•¸**ï¼šN = 50
- **ä¸»è¦ endpoint**ï¼šå‡è¡€æ™‚é–“å»¶é•·ï¼ˆâš ï¸ å·²é‡å°æ–°é©æ‡‰ç—‡é‡æ–°å®šç¾©ï¼‰
- **æ¬¡è¦ endpoint**ï¼šå®‰å…¨æ€§æŒ‡æ¨™
- **é—œéµæ’é™¤æ¢ä»¶**ï¼šåŸºæ–¼å®‰å…¨æ€§è€ƒé‡

---

### 4.2 Factor 5 excess with spontaneous thrombosis âš ï¸ åƒ…æ¨¡å‹é æ¸¬

| é …ç›® | å…§å®¹ |
|------|------|
| TxGNN åˆ†æ•¸ | 99.84% |
| è­‰æ“šç­‰ç´š | L5 |
| **é–‹ç™¼å»ºè­°** | Hold |
| **æ±ºç­–çµè«–** | Research Question |
| **Pharmacist å°æ‡‰** | æš«ä¸å»ºè­° |

**é˜»æ–·/Hold åŸå› **ï¼šç¼ºä¹ç›´æ¥è­‰æ“šæ”¯æŒ

#### è­‰æ“šå¯å¤–æ¨æ€§è©•ä¼°
### è­‰æ“šå¯å¤–æ¨æ€§è©•ä¼°

**è­‰æ“šç­‰ç´š**ï¼šL5
**è­‰æ“šé¡å‹**ï¼šæ¨¡å‹é æ¸¬

#### å¯å¤–æ¨ç†ç”±
| é¢å‘ | æ”¯æŒå¤–æ¨çš„ç†ç”± | å¼·åº¦ |
|------|---------------|------|
| æ©Ÿè½‰ç›¸é—œæ€§ | Warfarin æ¸›å°‘å‡è¡€å› å­åˆæˆï¼Œä½†ç¼ºä¹ç›´æ¥è­‰æ“š | å¼± |
| æ—ç¾¤ç›¸ä¼¼æ€§ | ç„¡ç›´æ¥æ”¯æŒ | å¼± |
| åŠ‘é‡å¯è¡Œæ€§ | ç„¡ç›´æ¥æ”¯æŒ | å¼± |

#### âš ï¸ é™åˆ¶æ¢æ¬¾
> æœ¬è­‰æ“šç­‰ç´šç‚º L5ï¼Œå­˜åœ¨ä»¥ä¸‹é™åˆ¶ï¼š
> 1. **ä¸å¯**ç›´æ¥ä½œç‚ºé–‹ç™¼æ±ºç­–ä¾æ“š
> 2. **ä¸å¯**ç›´æ¥ä½œç‚ºè©¦é©—è¨­è¨ˆä¾æ“š
> 3. **éœ€è¦**è£œå……ç›´æ¥è­‰æ“šå¾Œæ‰èƒ½å‡ç´š

**è‹¥è¦å‡ç´šè‡³ Hold/Conditional Go éœ€è£œé½Š**ï¼š
- [ ] ç›´æ¥è‡¨åºŠè©¦é©—è­‰æ“š
- [ ] æ©Ÿè½‰ç ”ç©¶

---

## 5. é©æ‡‰ç—‡æ¯”è¼ƒèˆ‡å„ªå…ˆé †åº

### 5.1 è­‰æ“šå¼·åº¦æ¯”è¼ƒ
| é©æ‡‰ç—‡ | è­‰æ“šç­‰ç´š | RCT | è§€å¯Ÿæ€§ | å‰è‡¨åºŠ | å¼·åº¦è©•åˆ† |
|-------|---------|-----|-------|-------|---------|
| Heparin cofactor 2 deficiency | L4 | 0 | 0 | 0 | ä¸­ |
| Factor 5 excess with spontaneous thrombosis | L5 | 0 | 0 | 0 | ä½ |
| Antithrombin deficiency type 2 | L4 | 0 | 0 | 0 | ä¸­ |

### 5.2 é–‹ç™¼å¯è¡Œæ€§æ¯”è¼ƒ
| é©æ‡‰ç—‡ | åŠ‘å‹ | åŠ‘å‹é¢¨éšª | å®‰å…¨æ€§é¢¨éšª | DDI é¢¨éšª | æ³•è¦è·¯å¾‘ | å¯è¡Œæ€§ |
|-------|-----|---------|-----------|---------|---------|-------|
| Heparin cofactor 2 deficiency | [Data Gap] | ä¸­ | ä¸­ | é«˜ | ä¸æ˜ | ä¸­ |
| Factor 5 excess with spontaneous thrombosis | [Data Gap] | ä¸­ | ä¸­ | é«˜ | ä¸æ˜ | ä½ |
| Antithrombin deficiency type 2 | [Data Gap] | ä¸­ | ä¸­ | é«˜ | ä¸æ˜ | ä¸­ |

### 5.3 å„ªå…ˆé–‹ç™¼é †åº
1. **Heparin cofactor 2 deficiency**ï¼šå› ç‚ºå…·æœ‰è¼ƒé«˜çš„ TxGNN åˆ†æ•¸å’Œæ–‡ç»æ”¯æŒï¼Œä½†éœ€è§£æ±º MOA ç¼ºå£ã€‚[ä¾†æºï¼šPubMed]
2. **Antithrombin deficiency type 2**ï¼šéœ€è§£æ±º MOA ç¼ºå£ã€‚[ä¾†æºï¼šPubMed]
3. **Factor 5 excess with spontaneous thrombosis**ï¼šéœ€æ›´å¤šç›´æ¥è­‰æ“šæ”¯æŒã€‚[ä¾†æºï¼šPubMed]

---

## 6. Risk Register

### 6.1 Evidence Risk
| é©æ‡‰ç—‡ | é¢¨éšª | åš´é‡åº¦ | ç·©è§£æªæ–½ |
|-------|-----|-------|---------|
| Heparin cofactor 2 deficiency | ç¼ºä¹æ©Ÿè½‰ç ”ç©¶ | é«˜ | é€²è¡Œæ©Ÿè½‰ç ”ç©¶ |

### 6.2 Safety Risk
| é¢¨éšª | å½±éŸ¿é©æ‡‰ç—‡ | åš´é‡åº¦ | ç·©è§£æªæ–½ |
|-----|-----------|-------|---------|
| è—¥ç‰©äº¤äº’ä½œç”¨ | å…¨éƒ¨ | é«˜ | åŠ å¼·å®‰å…¨æ€§ç›£æ¸¬ |

### 6.3 Regulatory/Operational Risk
| é¢¨éšª | æè¿° | åš´é‡åº¦ | ç·©è§£æªæ–½ |
|-----|------|-------|---------|
| æ³•è¦ | ç¼ºä¹å®Œæ•´çš„ MOA è³‡è¨Š | é«˜ | é€²ä¸€æ­¥çš„æ©Ÿè½‰ç ”ç©¶ |
| åŸ·è¡Œ | ç„¡è‡¨åºŠè©¦é©—æ”¯æŒ | é«˜ | é€²è¡Œå°è¦æ¨¡æ¢ç´¢æ€§è©¦é©— |

---

## 7. è£œä»¶è¿½è¹¤è¡¨

| # | ç¼ºå£ | é˜»æ–·æ€§ | è³‡æ–™ä¾†æº | è² è²¬äºº | æˆªæ­¢æ—¥ | ç‹€æ…‹ | å½±éŸ¿ç« ç¯€ | è£œä»¶å¾Œå¯é”å»ºè­° |
|---|-----|-------|---------|-------|-------|------|---------|--------------|
| 1 | MOA ç¼ºå£ | ğŸ›‘ | DrugBank | æœªæŒ‡æ´¾ | æœªå®š | â³ | Â§2.4, Â§4.1 | Conditional Go |

---

## 8. è£œä»¶å¾Œæ±ºç­–å‡ç´šè·¯å¾‘

```
ç•¶å‰ç‹€æ…‹ï¼šS1 â†’ æœ€é«˜å»ºè­°ï¼šResearch Question

è£œä»¶è·¯å¾‘ 1ï¼šè£œé½Š MOA è³‡æ–™
  â†’ å¯é”ï¼šS2 â†’ å‡ç´šè‡³ï¼šConditional Go
```

---

## é™„éŒ„ï¼šè³‡æ–™æ”¶é›†æ—¥èªŒ

| # | è³‡æ–™ä¾†æº | æŸ¥è©¢æ—¥æœŸ | æŸ¥è©¢æ¢ä»¶ | çµæœ | åŸå§‹çµæœé€£çµ |
|---|---------|---------|---------|------|-------------|
| 1 | TFDA | 2026-02-09 | drug=warfarin | 20 | [snapshot] |
| 2 | DDI | 2026-02-09 | drug=warfarin | 865 | [snapshot] |
| 3 | DrugBank | 2026-02-09 | drug=warfarin | 1 | [snapshot] |
| 4 | ClinicalTrials.gov | 2026-02-09 | drug=warfarin, disease=heparin cofactor 2 deficiency | 0 | [snapshot] |
| 5 | PubMed | 2026-02-09 | drug=warfarin, disease=heparin cofactor 2 deficiency | 5 | [snapshot] |

---

## æ–‡ä»¶ç‰ˆæœ¬è³‡è¨Š

| é …ç›® | å…§å®¹ |
|------|------|
| æ–‡ä»¶ç‰ˆæœ¬ | v1.0 |
| ç”¢ç”Ÿæ—¥æœŸ | 2026-02-09 |
| è³‡æ–™æˆªæ­¢æ—¥ | 2026-02-09 |
| Evidence Pack ç‰ˆæœ¬ | warfarin_v4_2026-02-09.json |
